#GastricCancer treatment can make eating difficult and lead to significant weight loss. Dr. @sundar__raghav, of @YaleCancer, highlights the importance of nutrition support and early access to clinical trials to help patients maintain strength. 🎥 https://t.co/5SPqBlXJ20

Excited for Phase 3 HERIZON-GEA01: zanidatamab + chemo ± tisle improved PFS vs tras + chemo for HER2+ GEA, with significant OS benefit for triplet and OS trend with doublet. Grateful to patients and investigators. Stay tuned for full results @OncoAlert https://t.co/Ohi299Sf2b

Sharing our work in the spatial biology of HER2+ gastric cancer @GUTJournal_BMJ. Figuring out and targeting the tumor microenvironment is an exciting time for cancer therapeutics. @FilippoPietran4 @josephjzhao @KoheiShitara

New Study Highlights Need for Coordinated Approach to Stomach Cancer Screening and Prevention https://t.co/7dyDvwMzVG @sundar__raghav @YaleCancer

Collaboration led by @JeeyunM @jitcancer @sitcancer: After 1 cycle chemo, 4/10 (40%) CLDN18.2+ tumors lost expression and 3/29 (10.3%) gained it. CLDN18.2+ TMEs are immune-inflamed yet fibrotic (TGF-β/ECM+) supports serial testing and combo strategies https://t.co/ITXHeMl3Bq

Tonight on #YaleCancerAnswers, @DrEricWiner speaks with @sundar__raghav, medical oncologist @YaleGICancers. Tune in + learn about breakthroughs, innovative treatments, + Dr. Sundar’s journey from Singapore ➡️ Yale. 🎧Listen live @wnpr 🔁Download @ApplePodcasts 💻Watch @YouTube

A pair of phase 1 trials evaluating antibody–drug conjugates identify potential strategies to treat advanced gastroesophageal #cancers and highlight the rapid expansion of claudin18.2-targeting drug development in solid tumors. News & Views from @KlempnerSam and @sundar__raghav

Targeting Claudin18.2 beyond monoclonal antibodies like zolbetixumab is arriving! In this article by @KlempnerSam and myself in @NatureMedicine we discuss two promising Claudin18.2 targeting Antibody-Drug Conjugates.

Moving immunotherapy into earlier stages of gastroesophageal cancers is a game changer for patients. In this study, we tease out the optimal chemotherapy backbone to combine with immunotherapy. https://t.co/97h7z88uho @josephjzhao @KlempnerSam

Examining periop Checkpoint inhibitor benefit in gastro-esophageal cancer... https://t.co/lNe0glc9aD Led by very talented @josephjzhao and Kennedy Ng. @sundar__raghav

It’s my great honor to write the editorial for the pivotal MATTERHORN study @NEJM @YJanjigianMD @ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.@OncoAlert @oncodaily https://t.co/ZhCzZdCFq4

Grateful for this award from MASCC. We have been working closely with @RichPaxman to build a device to reduce chemotherapy induced peripheral neuropathy. Awaiting results from the ICE COMPRESS trial. This has been a massive team effort! https://t.co/7W81EdZvsV

Gastric cancer @TheLancet https://t.co/wjuz9H4LWn 👏Excellent and comprehensive summary from screening to targeted therapies by @sundar__raghav @LizzySmyth1 @YJanjigianMD @KoheiShitara @HannekevanLaar1 @myESMO

A tribute to Dr. Agatsuma was a meaningful moment during my DESTINY-Gastric04 presentation at #ASCO25 with @NEJM publication. I deeply respect him and the entire team behind the development of T-DXd. @ASCO @OncoAlert @DaiichiSankyo @DaiichiSankyoUS @AstraZeneca @Oncology_at_AZ

📢It's #ESMO election time! I am delighted to be nominated for ESMO Director of Education 😊 ALL the nominees are fantastic representing the global @myESMO community 🌍 🙏for all the good wishes Rules this year for social media so that's it from me! Now please vote 🗳️

Cancer patients with B cell malignancies and differential expression of CD24, CDK14 and PLEKHG1 have highest risk of breakthrough infections after SARS-CoV2 vaccination https://t.co/BTmZRfyFDA Thank you @kuanrongchan @sundar__raghav for the collaboration! 😎

Thrilled to share our latest Review on Gastric Cancer in the @TheLancet covering the latest in the treatment and management of this illness @LizzySmyth1 @KoheiShitara @HannekevanLaar1 @MarkarSheraz @YJanjigianMD & Izuma Nakayama.

String of #AACR25 posts coming up! Proud of the work by @josephjzhao unraveling epigenetic mechanisms of peritoneal metastases in gastroesophageal cancers. @KlempnerSam @JohnnyOngCA

Published today simultaneously with #AACR25 our work on colorectal cancer peritoneal metastases in Clinical Cancer Research. https://t.co/hJRo0harRw slowly heading toward the goal of treating this difficult disease with novel therapeutics

Grateful to be given the opportunity to share our work on tumor evolution in gastric cancer and peritoneal metastases at #AACR25 with Dr Sun Young Rha @KlempnerSam @josephjzhao @choong_kun